

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/544,146
				Filing Date	May 5, 2006
				First Named Inventor	Shyam S. Mohapatra
				Art Unit	1635
				Examiner Name	Richard A. Schnizer
Sheet	1	of	5	Attorney Docket Number	USF.T193XC1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-2004/0002458 A1	01-01-2004	Seilhamer <i>et al.</i>	All
	U2	US-2005/0266093 A1	12-01-2005	Mohapatra	All
	U3	US-2005/0272650 A1	12-08-2005	Mohapatra	All
	U4	US-2006/0276382 A1	12-07-2006	Mohapatra	All
	U5	US-2007/0265204 A1	11-15-2007	Mohapatra <i>et al.</i>	All
	U6	US-2007/0116767 A1	05-24-2007	Mohapatra	All
	U7	US-2007/0009951 A1	01-11-2007	Mohapatra <i>et al.</i>	All
	U8	US-2008/0023325 A1	01-31-2008	Mohapatra <i>et al.</i>	All

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)					
	F1	WO 2003/028759 A1		04-10-2003	University of South Florida <i>et al.</i>	All	
	F2	WO 2003/070918 A2		08-28-2003	Ribozyme Pharmaceuticals, Incorporated	All	
	F3	WO 2003/092618 A2		11-13-2003	University of South Florida	All	
	F4	WO 2004/074314 A2		08-02-2004	University of South Florida	All	
	F5	WO 2004/076664 A2		09-10-2004	University of South Florida	All	
	F6	WO 2005/094420 A2		10-13-2005	University of South Florida	All	
	F7	WO 2005/105136 A1		11-10-2005	University of South Florida	All	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/544,146
Filing Date	May 5, 2006
First Named Inventor	Shyam S. Mohapatra
Art Unit	1635
Examiner Name	Richard A. Schnizer
Attorney Docket Number	USF.T193XC1

Sheet	2	of	5
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U9	US-2008/0070858 A1	03-20-2008	Mohapatra	All
	U10	US-2008/0075731 A1	03-27-2008	Mohapatra <i>et al.</i>	All
	U11	US-2008/0100279 A1	05-01-2008	Mohapatra <i>et al.</i>	All
	U12	US-5,931,069	11-03-1998	Barik	All
	U13	US-5,998,602	12-07-1999	Torrence <i>et al.</i>	All
	U14	US-6,489,306	12-03-2002	Mohapatra <i>et al.</i>	All
	U15	US-6,900,299	05-31-2005	Mohapatra <i>et al.</i>	All
	U16	US-7,118,888	10-10-2006	Mohapatra <i>et al.</i>	All
	U17	US-2001/0006951 A1	07-05-2001	Mohapatra <i>et al.</i>	All
	U18	US-2008/0249057 A1	10-09-2008	Mohapatra <i>et al.</i>	All
	U19	US-5,290,540	03-01-1994	Prince <i>et al.</i>	All
	U20	US-5,693,532	12-02-1997	McSwiggen <i>et al.</i>	All
	U21	US-6,586,579	06-01-2003	Huang <i>et al.</i>	All
	U22	US-7,354,908	04-08-2008	Mohapatra <i>et al.</i>	All

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	F8	WO 2007/127480 A2	11-08-2007	University of South Florida	All	
	F9	WO 2007/127487 A2	11-03-2007	University of South Florida	All	
	F10					
	F11					
	F12					

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/544,146
Filing Date	May 5, 2006
First Named Inventor	Shyam S. Mohapatra
Group Art Unit	1635
Examiner Name	Richard A. Schnizer
Attorney Docket Number	USF.T193XC1

Sheet 3 of 5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	BEHERA, A.K. <i>et al.</i> "Adenovirus-Mediated Interferon γ Gene Therapy for Allergic Asthma: Involvement of Interleukin 12 and STAT4 Signaling" <i>Human Gene Therapy</i> , September 2002, 13:1697-1709.	
	R2	BEHERA, A.K. <i>et al.</i> "2'-5' Oligoadenylate Synthetase Plays a Critical Role in Interferon- γ Inhibition of Respiratory Syncytial Virus Infection of Human Epithelial Cells" <i>The Journal of Biological Chemistry</i> , July 2002, 277(28):25601-25608.	
	R3	BITKO, V. <i>et al.</i> "Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses" <i>BMC Microbiology</i> , 2001, 1(34):1-11.	
	R4	BOSSERT, B. <i>et al.</i> "Respiratory Syncytial Virus (RSV) Nonstructural (NS) Proteins as Host Range Determinants: a Chimeric Bovine RSV with NS Genes from Human RSV IS Attenuated in Interferon-Competent Bovine Cells" <i>Journal of Virology</i> , May 2002, 76(9):4287-4293.	
	R5	BOSSERT, B. <i>et al.</i> "Nonstructural Proteins NS1 and NS2 of Bovine Respiratory Syncytial Virus Block Activation of Interferon Regulatory Factor 3" <i>Journal of Virology</i> , August 2003, 77(16):8661-8668.	
	R6	DORN, G. <i>et al.</i> "siRNA relieves chronic neuropathic pain" <i>Nucleic Acids Research</i> , 2004, 32(5):e49.	
	R7	HALLAK, L.K. <i>et al.</i> "Iduronic Acid-Containing Glycosaminoglycans on Target Cells Are Required for Efficient Respiratory Syncytial Virus Infection" <i>Virology</i> , 2000, 271:264-275.	
	R8	HELLERMAN, G.R. <i>et al.</i> "Genetic therapy: on the brink of a new future" <i>Genetic Vaccines and Therapy</i> , 2003, 1(1):1-2.	
	R9	JAIRATH, S. <i>et al.</i> "Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides" <i>Antiviral Research</i> , 1997, 33:201-213.	
	R10	JIN, H. <i>et al.</i> "Recombinant Respiratory Syncytial Viruses with Deletions in the NS1, NS2, SH, and M2-2 Genes are Attenuated <i>in Vitro</i> and <i>in Vivo</i> " <i>Virology</i> , 2000, 273:210-218.	
	R11	KUMAR, M. <i>et al.</i> "Intranasal IFN- γ gene transfer protects BALB/c mice against respiratory syncytial virus infection" <i>Vaccine</i> , 2000; 18:558-567.	
	R12	KUMAR, M. <i>et al.</i> "Intranasal Gene Transfer by Chitosan-DNA Nanospheres Protects BALB/c Mice Against Acute Respiratory Syncytial Virus Infection" <i>Human Gene Therapy</i> , August 2002, 13:1415-1425.	
	R13	KUMAR, M. <i>et al.</i> "Chitosan IFN- γ -pDNA Nanoparticle (CIN) Therapy for Allergic Asthma" <i>Genetic Vaccines and Therapy</i> , 2003, 1(3):1-10.	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

5

Complete if Known

Application Number	10/544,146
Filing Date	May 5, 2006
First Named Inventor	Shyam S. Mohapatra
Group Art Unit	1635
Examiner Name	Richard A. Schnizer
Attorney Docket Number	USF.T193XC1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R14	LEAMAN, D.W. <i>et al.</i> "Targeted Therapy of Respiratory Syncytial Virus in African Green Monkeys by Intranasally Administered 2-5A Antisense" <i>Virology</i> , 2002, 292:70-77.	
	R15	MATSUSE, H. <i>et al.</i> "Recurrent Respiratory Syncytial Virus Infections in Allergen-Sensitized Mice Lead to Persistent Airway Inflammation and Hyperresponsiveness" <i>The Journal of Immunology</i> , 2000, 164:6583-6592.	
	R16	MOHAPATRA, S. "Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus" <i>The Pediatric Infectious Disease Journal</i> , February 2003, 22(2):S100-S104.	
	R17	MURPHY, B.R. "Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics" <i>The Journal of Clinical Investigation</i> , July 2002, 110(1):21-27.	
	R18	LAZAR, I. <i>et al.</i> "Human Metapneumovirus and Severity of Respiratory Syncytial Virus Disease" <i>Emerging Infectious Diseases</i> , July 2004, 10(7):1318-1320, NCBI accession no. M74568.	
	R19	DEPLANCHE, M. <i>et al.</i> "In vivo evidence for quasispecies distributions in the bovine respiratory syncytial virus genome" <i>Journal of General Virology</i> , 2007, 88:1260-1265, NCBI accession no. NC_001989.	
	R20	PAN, W. <i>et al.</i> "Isolation of virus-neutralizing RNAs from a large pool of random sequences" <i>Proc. Natl. Acad. Sci. USA</i> , December 1995, 92:11509-11513.	
	R21	SCHLENDER, J. <i>et al.</i> "Bovine Respiratory Syncytial Virus Nonstructural Proteins NS1 and NS2 Cooperatively Antagonize Alpha/Beta Interferon-Induced Antiviral Response" <i>Journal of Virology</i> , 2000, September 2000, 74(18):8234-8242.	
	R22	SOUTSCHEK, J. <i>et al.</i> "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs" <i>Nature</i> , November 2004, 432:173-178.	
	R23	SPANN, K.M. <i>et al.</i> "Suppression of the Induction of Alpha, Beta, and Gamma Interferons by the NS1 and NS2 Proteins of Human Respiratory Syncytial Virus in Human Epithelial Cells and Macrophages" <i>Journal of Virology</i> , April 2004, 78(8):4363-4369.	
	R24	STEIN, C.A. "The experimental use of antisense oligonucleotides: a guide for the perplexed" <i>The Journal of Clinical Investigation</i> , 2001, 108:641-644.	
	R25	TENG, M.N. <i>et al.</i> "Altered Growth Characteristics of Recombinant Respiratory Syncytial Viruses Which Do Not Produce NS2 Protein" <i>Journal of Virology</i> , January 1999, 73(1):466-473.	
	R26	TENG, M.N. <i>et al.</i> "Recombinant Respiratory Syncytial Virus That Does Not Express the NS1 or M2-2 Protein Is Highly Attenuated and Immunogenic in Chimpanzees" <i>Journal of Virology</i> , October 2000, 74(19):9317-9321.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

5

of

5

Complete if Known

Application Number	10/544,146
Filing Date	May 5, 2006
First Named Inventor	Shyam S. Mohapatra
Group Art Unit	1635
Examiner Name	Richard A. Schnizer
Attorney Docket Number	USF.T193XC1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R27	ZHANG, W. <i>et al.</i> "Attenuation of dengue virus infection by adeno-associated virus-mediated siRNA delivery" <i>Genetic Vaccines and Therapy</i> , 2004, 2(8):1-10.	
	R28	ZHANG, X. <i>et al.</i> "Small Interfering RNA Targeting Heme Oxygenase-1 Enhances Ischemia-Reperfusion-induced Lung Apoptosis" <i>The Journal of Biological Chemistry</i> , March 2004, 279(11):10677-10684.	
	R29	ZHAO, C.A. <i>et al.</i> "Inhibition of respiratory syncytial virus replication in cultured cells by RNA-cleaving DNzyme" <i>Chinese Journal of Pediatrics</i> , 2003, 41(8): 594-597, Medline XP002513933 Database accession No. NLM14744382.	
	R30	REICH, S.J. <i>et al.</i> "Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model" <i>Molecular Vision</i> , 2003, 9:210-216.	
	R31	SUBRAMANYA, S. <i>et al.</i> "Targeted Delivery of Small Interfering RNA to Human Dendritic Cells to Suppress Dengue Virus Infection and Associated Proinflammatory Cytokine Production" <i>Journal of Virology</i> , March 2010, 84(5):2490-2501.	
	R32		
	R33		
	R34		
	R35		
	R36		
	R37		
	R38		
	R39		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.